MDxHealth SA (NASDAQ:MDXH) Short Interest Update

Posted by George Bondi on Jun 15th, 2026

MDxHealth SA (NASDAQ:MDXH – Get Free Report) saw a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 457,830 shares, a decrease of 49.7% from the May 14th total of 910,289 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average trading volume of 718,711 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in MDxHealth by 213.9% in the 1st quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after buying an additional 29,638 shares during the period. Renaissance Technologies LLC increased its stake in MDxHealth by 21.8% in the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after buying an additional 54,600 shares during the period. Perkins Capital Management Inc. increased its stake in MDxHealth by 7.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after buying an additional 97,500 shares during the period. XTX Topco Ltd increased its stake in MDxHealth by 220.0% in the 4th quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock valued at $146,000 after buying an additional 28,090 shares during the period. Finally, Millennium Management LLC increased its stake in MDxHealth by 328.3% in the 4th quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock valued at $417,000 after buying an additional 89,553 shares during the period.

MDxHealth Stock Up 2.3%

Shares of MDXH stock traded up $0.01 during trading hours on Monday, reaching $0.55. 482,830 shares of the stock traded hands, compared to its average volume of 746,975. MDxHealth has a 1-year low of $0.51 and a 1-year high of $5.33. The business has a fifty day moving average price of $1.46 and a 200 day moving average price of $2.71.

MDxHealth (NASDAQ:MDXH – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. As a group, equities research analysts anticipate that MDxHealth will post -0.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MDXH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. TD Cowen reiterated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Lake Street Capital dropped their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, BTIG Research dropped their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.63.

View Our Latest Analysis on MDXH

MDxHealth Company Profile

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.